Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Delmar Pharmaceuticals Inc (DMPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the Company...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced four poster...

DMPI : 0.91 (-3.70%)
Today's Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Lipocine shares were on fire after receiving an upgrade and a price target of $21 a share. Shares of DelMar Pharmaceuticals also soared higher despite any...

DMPI : 0.91 (-3.70%)
LPCN : 1.55 (unch)
DelMar Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 20, 2018 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) will be discussing their earnings results in their Q3 Earnings Call to be held on February 20, 2018 at 4:30 PM...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results

VANCOUVER, British Columbia and MENLO PARK, Calif. , Feb. 14, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the second quarter...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S....

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma

VANCOUVER, British Columbia and MENLO PARK, Calif. , Dec. 26, 2017 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused...

DMPI : 0.91 (-3.70%)
This Morning's Technical Outlook on Biotech Stocks -- DelMar Pharma, Galena Biopharma, Heat Biologics, and Idera Pharma

In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on DMPI, GALE, HTBX, and IDRA which is a click away at www.wallstequities.com/registration....

DMPI : 0.91 (-3.70%)
GALE : 0.26 (-7.14%)
HTBX : 1.12 (unch)
IDRA : 1.54 (-1.28%)
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today provided an overview of three scientific posters...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 14, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) will be discussing their earnings results in their Q2 Earnings Call to be held on November 14, 2017 at 4:30 PM...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the first quarter...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results

VANCOUVER, British Columbia and MENLO PARK, Calif. , Nov. 13, 2017 /PRNewswire/ --  DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the appointment of Mr. Saiid Zarrabian...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer

VANCOUVER, British Columbia and MENLO PARK, Calif. , Nov. 7, 2017 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of new data at...

DMPI : 0.91 (-3.70%)
ONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors

NEW YORK, NY / ACCESSWIRE / October 24, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) VAL-083, a novel alkylating agent that has demonstrated potency against brain tumor cells and can overcome resistance...

DMPI : 0.91 (-3.70%)
SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

NEW YORK, NY / ACCESSWIRE / October 10, 2017 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today...

DMPI : 0.91 (-3.70%)
Investor Network: DelMar Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / October 4, 2017 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) will be discussing their earnings results in their Q4 Earnings Call to be held October 4, 2017 at 4:30 PM Eastern...

DMPI : 0.91 (-3.70%)
DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals (Nasdaq: DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American...

DMPI : 0.91 (-3.70%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR -0.76 , HFC -0.76 , ABMD +2.27 , CAR +0.46 , URBN +0.92
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures ended the Wednesday session with most contracts 5 to 6 cents higher, following wheat. Wednesday’s weekly EIA report showed ethanol production for the week that ended 4/20 dropping 24,000 barrels per day to 985,000 bpd. That is the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar